Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,712,000
+2,000 (0.12%)
At close: Feb 11, 2026

Revenue by Geography

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14
Domestic Revenue
144.43B135.18B114.57B
Domestic Revenue Growth
6.84%17.99%-25.96%
Europe Revenue
3.06T2.96T2.35T
Europe Revenue Growth
3.22%25.89%31.80%
USA Revenue
1.55T1.17T971.06B
USA Revenue Growth
32.00%20.91%13.71%
Other Geographic Revenue
278.82B274.75B255.12B
Other Geographic Revenue Growth
1.48%7.70%23.43%

Revenue Breakdown

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14
Contract Development and Manufacturing Organization (CDMO) Revenue
3.01T2.67T
Contract Development and Manufacturing Organization (CDMO) Revenue Growth
12.54%14.41%
Biopharmaceutical Development and Commercialization Revenue
1.54T1.02T
Biopharmaceutical Development and Commercialization Revenue Growth
50.71%53.71%

Revenue Breakdown 2

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14
Product Revenue
4.79T4.17T3.40T
Product Revenue Growth
15.08%22.39%22.03%
Other Revenue
238.67B382.25B291.61B
Other Revenue Growth
-37.56%31.09%37.17%

EBIT

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14
Contract Development and Manufacturing Organization (CDMO) Operating Profit
1.12T1.09T
Contract Development and Manufacturing Organization (CDMO) Operating Profit Growth
2.86%18.85%
Biopharmaceutical Development and Commercialization Operating Profit
200.69B25.46B
Biopharmaceutical Development and Commercialization Operating Profit Growth
688.23%-62.58%
Updated Jun 30, 2025. Data Source: Fiscal.ai.